Search clinical trials for: EGFR806-specific chimeric antigen receptor (CAR) T cell

Total 233 results

Seattle Children's Hospital

Active, not recruiting

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

Glioma | Ependymoma | Medulloblastoma | Pineoblastoma | Central Nervous System Tumor, Pediatric | Germ Cell Tumor | Atypical Teratoid/Rhabdoid Tumor | Primitive Neuroectodermal Tumor | Choroid Plexus Carcinoma

United States
Zhujiang Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...

Recruiting

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Myelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)

China
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors

Glioma | Ependymoma | Medulloblastoma | Pineoblastoma | Central Nervous System Tumor, Pediatric | Germ Cell Tumor | Atypical Teratoid/Rhabdoid Tumor | Primitive Neuroectodermal Tumor | Choroid Plexus Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Breast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Leptomeninges

United States
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

CAR | Malignant Tumors

China
First Affiliated Hospital of Harbin Medical University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

Pancreatic Cancer | CAR

China
Shanghai GeneChem Co., Ltd.
Shanghai Cancer Hospital, China

Unknown

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Carcinoma, Hepatocellular | Colorectal Cancer Metastatic | Pancreatic Cancer Metastatic

China
Sinobioway Cell Therapy Co., Ltd.
Jiangsu Cancer Institute & Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma (EECPL)

Lymphoma

China
Fondazione Italiana Linfomi - ETS
Kite, A Gilead Company

Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell

Italy
John Lister
Miltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed Lymphoma

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | CAR

China
Cellular Biomedicine Group Ltd.

Recruiting

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Beijing 302 Hospital
Tsinghua University

Unknown

Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection (TCTIWHI)

HIV-1

China
National Taiwan University Hospital

Not yet recruiting

CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies

Relapsed/Refractory B-Cell Malignancies
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Withdrawn

Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

Classical Hodgkin Lymphoma | Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Seattle Children's Hospital

Recruiting

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Glioma | Ependymoma | Medulloblastoma, Childhood | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Central Nervous System Tumor | Germ Cell Tumor | Atypical Teratoid/Rhabdoid Tumor | Primitive Neuroectodermal Tumor | Choroid Plexus Carcinoma | Pineoblastoma, Childhood

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University; NanJing PLA...

Completed

Chimeric Antigen Receptor T Cells Targeting Glypican-3

Hepatocellular Carcinoma

China
Beijing Boren Hospital

Recruiting

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Relapse/Recurrence | T-cell Leukemia/Lymphoma | Refractory T Lymphoblastic Leukemia/Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Lymphoma, B-Cell | Leukemia, B-cell

China
Xuanwu Hospital, Beijing
Beijing Mario Biotech Company; Hebei Senlang BIotech Company; Beijing HuiNengAn...

Recruiting

Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas

Glioma | Malignant Glioma of Brain | Recurrence Tumor

China
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Xijing Hospital

Unknown

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

Recurrent Glioblastoma | CD147 Positive

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 (CART33)

Relapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid Leukemia

China
The Affiliated Hospital of Qingdao University

Recruiting

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

Gastric Cancer

China
The Affiliated Hospital of Qingdao University

Recruiting

XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

Colon Cancer

China
Changhai Hospital
Shanghai Ultra-T Immune Therapeutics Co. LTD

Not yet recruiting

A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System

Digestive Tumor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Zhengzhou University

Unknown

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Angioimmunoblastic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | T Lymphoblastic Leukemia/Lymphoma | Extramedullary NK-T-cell Lymphoma, Nasal Type | Peripheral T-cell Lymphoma, Nonspecific | T-cell Lymphoblastic Leukemia

China
Hebei Yanda Ludaopei Hospital

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Immune Thrombocytopenia | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Primary Biliary Cholangitis
The First Affiliated Hospital with Nanjing Medical...

Unknown

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Peking University
Gracell Biopharmaceuticals, Inc.

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Soochow University

Recruiting

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

T-ALL

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital; The First People's Hospital of Hefei; Hefei Binhu...

Unknown

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Unknown

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic Leukemia

China
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
Zhejiang University
Innovative Cellular Therapeutics Co., Ltd.

Unknown

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Lymphoma

China
Cellular Biomedicine Group Ltd.
Shanghai Tongji Hospital, Tongji University School of Medicine

Unknown

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Refractory or Relapsed Non-Hodgkin Lymphoma

China
Cellular Biomedicine Group Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

China

Search clinical trials for: EGFR806-specific chimeric antigen receptor (CAR) T cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations